Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKART-1 Phase 2 study of KTE-X19 in relapsed/refractory mantle cell lymphoma or B-precursor acute lymphoblastic leukemia in Japan
jRCT2063230095Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL) (2 cohorts), sponsored by Gilead Sciences. Primary endpoints: Objective response rate and Overall complete remission rate. Started Mar 2024; status: active, not recruiting.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2063230095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063230095.